[Experimental study on cetuximab and dendritic cells killing head and neck squamous cell]

Area of Science:

• Immunotherapy
• Oncology
• Cell Biology

Background:

• Head and neck squamous cell carcinoma (HNSCC) remains a significant health challenge.
• Current treatment options for HNSCC have limitations.
• Targeted therapies and immunotherapies are areas of active research.

Purpose of the Study:

• To investigate the combined effect of cetuximab and dendritic cells (DCs) on killing HNSCC.
• To explore a novel therapeutic approach for HNSCC patients.

Main Methods:

• Dendritic cells (DCs) were generated in vitro from peripheral blood monocytes.
• DC maturation markers (CD83, CD86) were analyzed.
• Cytotoxicity and apoptosis of HNSCC cells were assessed using MTT and flow cytometry.
• Western blot was used to analyze EGFR and pEGFR expression.

Main Results:

• Successful in vitro induction of mature DCs (mDCs) expressing higher levels of CD83 and CD86.
• Cetuximab combined with DCs significantly enhanced HNSCC cytotoxicity and apoptosis (P < 0.05).
• pEGFR levels decreased with increasing cetuximab concentration (P < 0.05), but no significant difference was observed between cetuximab alone and cetuximab plus DCs.

Conclusions:

• Cetuximab and DCs exhibit synergistic effects in enhancing HNSCC cell killing.
• The combination therapy shows potential as a novel treatment strategy for HNSCC.